Drugs / UTAA91
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06982547 | Jun 2025 → Dec 2027 expected | rheumatoid arthritis | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07000682 | May 2025 → Dec 2027 expected | systemic sclerosis | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 0 | NCT06970951 | May 2025 → Jun 2026 overdue | dry eye syndrome, idiopathic inflammatory myopathy, rheumatoid arthritis, systemic lupus erythematosus +1 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UTAA91 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07000682 ↗ |
| Modality | Cell therapy | “CAR-modified gamma delta T cells” NCT07000682 ↗ |
| Route | Other | “eligible subjects will receive an infusion of UTAA91 injection.” NCT06970951 ↗ |